DNMTs甲基化修饰FAM8A1抑制ERAD调控慢性阻塞性肺疾病发病的作用机制研究
批准号:
82060013
项目类别:
地区科学基金项目
资助金额:
34.0 万元
负责人:
张雅囡
依托单位:
学科分类:
慢性阻塞性肺疾病
结题年份:
2024
批准年份:
2020
项目状态:
已结题
项目参与者:
张雅囡
中文摘要
内质网应激及其诱导的细胞凋亡是慢阻肺机制研究的热点。内质网相关性降解途径(ERAD)是清除内质网错误折叠蛋白的主要机制。FAM8A1以复合体的形式在ERAD中起核心作用。我们前期研究发现,FAM8A1在慢阻肺中表达降低。在16HBE细胞中沉默FAM8A1会引起细胞凋亡。生物信息学分析示FAM8A1转录起始点上下游富含CpG岛,其可能受DNA甲基化调控。甲基转移酶家族(DNMTs)是催化DNA甲基化的关键酶。前期体外实验发现,香烟烟雾提取物能够诱导DNMTs的表达。故推测FAM8A1可能被DNMTs甲基化修饰调控,抑制其介导的ERAD,促进慢阻肺的发病。本课题拟通过临床样本验证FAM8A1表达,培养气道及肺泡上皮细胞阐述CSE通过DNMTs抑制FAM8A1表达及其介导ERAD的机制,建立慢阻肺大鼠模型明确FAM8A1介导的内质网稳态在肺上皮细胞凋亡中的保护性作用。为慢阻肺的治疗提供新方向。
英文摘要
Stress of the endoplasmic reticulum (ER) organelle, which is responsible for folding, processing, and trafficking of proteins in the cells is involved in the regulation of COPD pathogenesis. Imbalance in the ER load of misfolded proteins relative to ER folding capacity causes ER stress (ERS) and induces apoptosis which is the research hotspot in COPD. Misfolded ER proteins are removed by a process, called ER-associated protein degradation (ERAD), an evolutionarily conserved process in which substrates are retro-translocated into the cytosol, polyubiquitinated, and degraded by the proteasome. FAM8A1, a essential component in ubiquitin ligase complex, plays a central role in ERAD. We have found that FAM8A1 expressed lower in COPD than the non-COPD control group. Further silencing FAM8A1 in 16HBE cells induce cell apoptosis. Bioinformatics analysis showed that the upstream and downstream of FAM8A1 transcription start site was rich in CpG islands, which may be regulated by DNA methylation. Methyltransferase family (DNMTs) are key enzymes that catalyzes DNA methylation. The vitro experiments early suggested that cigarette smoke extract (CSE) induce the expression of DNMTs. We thus hypothesized that DNMTs methylation-modified FAM8A1 inhibits the ERAD and promote the development of COPD. This study intends to confirm the expression of FAM8A1 through clinical samples, explain the mechanism of CSE inhibiting FAM8A1 and FAM8A1-mediated ERAD through DNMTs in airway and alveolar epithelial cells , and establish a COPD rat model to clarify FAM8A1 mediated ER homeostasis preventing lung epithelial cells apoptosis, which provides a basis for improving the intervention strategy and developing new therapeutic targets for COPD treatment.
内质网应激及其诱导的细胞凋亡是慢阻肺发病的重要机制。内质网相关降解途径(ERAD)通过清除错误折叠蛋白缓解内质网应激。FAM8A1在ERAD中起重要作用。本研究通过人体、细胞、动物三个层面及生物信息学分析,探究FAM8A1的表达及其功能、FAM8A1与甲基转移酶(DNMTs)的相互作用及其上游调控机制。研究中,临床肺组织标本验证FAM8A1的表达;细胞实验及动物模型验证FAM8A1在ERAD途径中的功能以及DNMT3A对其调控作用。生物信息学分析筛选内质网应激的关键调节因子(EGF),体内和体外实验验证EGF对DNMT3A/FAM8A1信号通路的调控机制。研究结果,通过收集人肺组织检测FAM8A1、DNMTs等基因,明确其表达及与临床指标的相关性。细胞实验中,通过构建FAM8A1过表达载体,同时使用ERAD 通路抑制剂干预,发现FAM8A1可能通过增强ERAD来减轻慢阻肺支气管上皮细胞损伤和内质网应激;分别将DNMT3A和FAM8A1的siRNA转染BEAS-2B细胞,发现DNMT3A沉默可能通过上调FAM8A1增强ERAD,减轻支气管上皮细胞损伤和内质网应激。EGF作为生物信息学预测的慢阻肺内质网应激的关键调节因子,在慢阻肺中的表达存在差异;预测EGF/ERBB2是DNMT3A/FAM8A1的上游通路。验证实验:将EGF的siRNA转染BEAS-2B细胞,阻断EGF/ERBB2通路可降低DNMT3A表达,并增加FAM8A1表达;动物实验中,在慢阻肺小鼠肺上皮组织中发现EGF、ERBB2和DNMT3A上调,FAM8A1下调。使用AG-825(ERBB2抑制剂)联合ESI(ERAD抑制剂)处理慢阻肺小鼠,发现阻断EGF/ERBB2通路可增强ERAD以减轻小鼠COPD。因此,本研究显示EGF/ERBB2抑制内质网相关降解途径,通过增加DNMT3A降低FAM8A1,促进慢阻肺的发生发展。这为慢阻肺的诊治提供新的视角。
国内基金
海外基金